Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC022: Combination Therapy Adaptive Platform Trial for Pediatric Diffuse Midline Gliomas
2022-000636-40Phase 2Active
- Sponsor
- Pacific Pediatric Neuro-Oncology Consortium
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dordaviprone and paxalisib in diffuse midline glioma (DMG) and malignant glioma (2 cohorts), sponsored by Pacific Pediatric Neuro-Oncology Consortium. Primary endpoint: Progression-free survival at 6 months (PFS6). Started Jul 2022; status: active.
02
Drugs
dordavipronepaxalisib
03
Conditions
diffuse midline glioma (DMG)malignant glioma
Beyond the preview
Go deeper on 2022-000636-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000636-40.